Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective

Anneke D. van Dijk, Eveline S.J.M. de Bont, Steven M. Kornblau

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Introduction: The biological heterogeneity of acute myeloid leukemia (AML) complicates personalized medicine. Individual prognosis is typically based on the presence of chromosomal and genetic lesions. Nevertheless, these classifications often lack a priori information about response to therapy. Since the protein expression landscape reflects the functional activity state of cells, we hypothesize that analyzing this can be used for the identification of protein activity markers to provide better risk stratification as well as may provide targeted therapeutic guidance in AML. Areas covered: Herein, we review recently new adopted drugs in the treatment for AML and discuss how quantitative proteomic techniques may contribute to better therapeutic selection in AML. Expert commentary: The net functional state of the cell is defined by the activity of protein within all the pathways that are active in the cell. Recognition of the proteomic profile of the leukemic blast could, therefore, complement current classification systems by providing a better a priori description of what pathways are important within a cell as a guide to the selection of therapy for the patient.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalExpert Review of Proteomics
Issue number1
StatePublished - 2 Jan 2020
Externally publishedYes


  • AML
  • Proteomics
  • RPPA
  • acute leukemia
  • reverse-phase protein arrays
  • targeted therapy


Dive into the research topics of 'Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective'. Together they form a unique fingerprint.

Cite this